Business Wire

UrsaNav trials eLoran as vital GNSS backup using ADVA’s grandmaster clock solution

Share

ADVA (FSE: ADV) today announced that UrsaNav and ADVA have conducted an enhanced long-range navigation (eLoran) field trial using UrsaNav’s eLoran receiver and ADVA’s Oscilloquartz grandmaster clock technology. The successful demo shows that eLoran offers a robust and reliable backup for GPS and other GNSS and could be used to provide an assured position, navigation, and timing (PNT) service. The trial follows US federal executive order 13905 aimed at strengthening national resilience through PNT services, including protecting critical infrastructure such as electrical power grid and communication networks from rising cyber threats. By harnessing ADVA’s flexible OSA 5420 Series, designed with assured PNT (aPNT) technology, UrsaNav has shown that eLoran can provide a new layer of protection and significantly boost timing resilience and security.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005101/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s synchronization technology is key for critical infrastructure that needs ultra-reliable aPNT solutions (Photo: Business Wire)

“The success of this field trial demonstrates how eLoran, as part of ADVA’s assured PNT solution, can serve as a crucial backup for GPS. We have shown how our technology enables ADVA’s grandmaster clock to receive UTC timing from the eLoran system for a period of several days with the same accuracy and stability as GPS. Of course, this capability is extensible to other GNSS as well. eLoran is far less vulnerable to unintentional jamming and spoofing disruptions or intentional attacks, thereby delivering nanosecond precision with even more resilience,” said Charles Schue, CEO, UrsaNav. “By partnering with ADVA, we’ve been able to show that our eLoran receiver interoperates with the best network timing toolkit available. The OSA 5420 Series is a great product – highly efficient and easy to operate. Together with ADVA, we’re paving the way for tomorrow’s more robust assured PNT synchronization architecture.”

Across the globe, essential services and entire industries are increasingly reliant on GNSS for PNT information. But these satellite systems are inherently susceptible to interference, which could have disastrous consequences. A major disruption may result in billions of dollars of economic damage as well as a serious risk of loss of life. eLoran is one of the key technologies that could provide protection, with governments including the US exploring its potential as an alternative PNT source. UrsaNav’s latest trial harnessed the OSA 5420 Series grandmaster clock with inbuilt GNSS receiver. Timing stability from GPS was measured for several days. This was then replaced with eLoran for the same period with no loss of stability. What’s more, the test was conducted indoors where GNSS signals are not usually available, potentially extending the availability of precise UTC timing to many more environments.

“Commercially available GNSS jammers and spoofers are easy and cheap for attackers to construct. That’s part of the reason why we’re seeing a growing number of incidents across the world of blocked or misleading signals. If power utilities, enterprises, service providers and governments continue to rely on GNSS alone, it’s only a matter of time before the consequences become very serious. That’s why we’re committed to tackling GNSS vulnerabilities with advanced technologies like our ePRTC offering, cesium atomic clocks and our optical timing channel solution,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Now that UrsaNav has demonstrated the power of our OSA 5420 Series to utilize eLoran in the event of outages, we have another very important tool to ensure the quality and availability of time-sensitive services.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

About UrsaNav

Ursa Navigation Solutions (“UrsaNav”) is the world’s leading supplier of Low Frequency PNT solutions, with proven performance delivering the latest technology for eLoran systems, including transmission, control, monitoring, and reference site equipment. From initial concept through operational certification, UrsaNav provides every aspect of the provider or user experience, including commercial and military PNT solutions, critical infrastructure protection, and legacy system transformation. www.ursanav.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swappable Announces Partnership with Esports T1's Dota 2 Team24.9.2021 14:34:00 EEST | Press release

Swappable, an NFT (Non-Fungible Token) interface for high-profile and exclusive digital collectibles, has announced its partnership with T1's Dota 2 team, the popular esports team for the upcoming International 10 - Dota 2 World Championship in Bucharest, Romania. T1 is not just an esports team but a pop culture phenomenon with millions of fans worldwide. The team embodies a blend of lifestyle, creativity and attitude, fresh from the source of Seoul & LA. As part of the collaboration, T1 will auction their first-ever NFTs (digital collectibles) on Swappable for T1’s Genesis Collection. With the first auction starting Friday September 24th, T1 will release a series of NFTs each possessing utility features such as special access to T1's Dota 2 team players and more. Visit Swappable for more information. “We are excited to partner with a leading organization in the esports industry. It is also a chance for T1 fans to pick the very first digital collectibles ever created by this legendary

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-1924.9.2021 14:00:00 EEST | Press release

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3. SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with mild to moderate COVID-19. It is being assessed in the ACTIV-2 trial funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) in collaboration with the AIDS Clinical Trials Group. SAB-185 is advancing to the Phase 3 trial based on meeting pre-defined graduation crite

NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device24.9.2021 12:00:00 EEST | Press release

As COVID-19 vaccination has raised the issue of thrombosis, Dr. Chih-Kuang Yeh, Distinguished Professor of the Department of Biomedical Engineering and Environmental Sciences, has led a research team to developed the world's first ultrasonic vortex thrombolytic device and to treat thrombosis quickly and safely. The research has been published in Proceedings of the National Academy of Sciences (PNAS) in 2021. Moreover, U.S. and EU patents are granted, with more applications on the way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210924005015/en/ (Photo: National Tsing Hua University) The device is developed to solve two common thrombosis called pulmonary embolism (PE) and deep vein thrombosis (DVT), which have global prevalence of 10 million new cases annually. DVT is the main cause of PE, and PE can cause heart failure and has mortality rate up to 65%. Professor Yeh explained that the current treatment options includes dr

Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease24.9.2021 11:00:00 EEST | Press release

Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA® (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone disease. The data show that adults with XLH experience substantial pain, stiffness, fatigue and impairment in physical and ambulatory function. Treatment with CRYSVITA was associated with a significant improvement from baseline after 96 weeks.1 The data are from a randomised, double-blind, placebo-controlled, phase 3 study with an open-label extension to assess the efficacy and safety of CRYSVITA in adults with XLH.2 The study met its primary endpoint, showing a statistically significant effect in increasing serum phosphorus concentrations at 24 weeks, compared to placebo.3 After 24 weeks, all patients were switched to CRYSVITA treatment and data was collected on metabolic and biochemical markers, patient reported outcomes (PROs) and measures of

XPeng Backed HT Aero Unveils Flying Vehicle City Usage Scenarios24.9.2021 08:58:00 EEST | Press release

HT Aero, an urban air mobility (UAM) company in which XPeng Inc. is an investor, today unveiled future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 ("X2"), including autonomous flight take-off and landing for specific city scenarios, back-end scheduling, charging and flight control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923006034/en/ XPeng X2 flying vehicle (Photo: Business Wire) XPeng X2 will present at the 13th Airshow China 2021, starting on September 28 in Zhuhai, Guangdong Province. X2 is equipped with a robust, highly intelligent flight control system and superior autonomous flying capability, able to conduct autonomous flight route planning, all-round real-time imaging, real-time flight monitoring, two-way real-time communications, all-round environmental perception and autonomous return and landing. It is powered by a highly efficient and convenient charging system, leveraging XP

Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER24.9.2021 08:35:00 EEST | Press release

Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic diseases, announces the consolidation of its development of innovative natural health solutions, by integrating the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER. This program should allow to develop a bank of high-potential strains selected by ADECAL-Technopole and IFREMER since 2013 in New Caledonia as part of the "AMICAL" joint research project. Valbiotis will carry out the work necessary to demonstrate the health benefits of these microalgae strains at its preclinical platform in Riom, with a view to filing new patents. Once this scientific validation has been achieved, production will be ensured in New Caledonia for the industrial scale-up, thanks to existing and operational pilot infrastructure for which the technology and

Illumination and Nintendo Announce Theatrical Release Date and Voice Cast for the Super Mario Bros. Animated Film24.9.2021 02:46:00 EEST | Press release

Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that their new animated film based on the world of Super Mario Bros. will be released worldwide during the 2022 holiday season. Universal Pictures will release the film in North America on December 21, 2022, with the release schedule for additional countries and regions to be announced at a future date. The film will be co-financed by Universal Pictures and Nintendo. In addition, the two companies announced the voice actors for the characters Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), Donkey Kong (Seth Rogen), Cranky Kong (Fred Armisen), Kamek (Kevin Michael Richardson) and Spike (Sebastian Maniscalco). Each voice actor was cast for their ability to capture the unique spirit of their c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom